hERG assay publications

	Citation Score
1. Relationships between preclinical cardiac electrophysiology, clinical QT interva Cardiovasc Res 58: 32-45. (2003).	571.4
2. Molecular basis of transient outward potassium current downregulation in human h Circulation 98: 1383-93. (1998).	317.2
3. Pentamidine-induced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Ther 312: 316-23. (2005).	200.0
4. Tissue and species distribution of mRNA for the IKr-like K+ channel, erg. Circ Res 80: 261-8. (1997).	166.7
5. In vivo identification of genes that modify ether-a-go-go-related gene activity Proc Natl Acad Sci U S A 101: 11773-8. (2004).	149
6. Effects of calcium channel blockers on cloned cardiac K+ channels IKr and IKs. Therapie 55: 195-202. (0).	115
7. Electrical alternans and hemodynamics in the anesthetized guinea pig can discrim J Pharmacol Toxicol Methods 55: 78-85. (0).	113
8. KvLQT1 modulates the distribution and biophysical properties of HERG. A novel al J Biol Chem 279: 1233-41. (2004).	106
9. Glucose- and arginine-induced insulin secretion by human pancreatic beta-cells: FASEB J 14: 2601-10. (2000).	105.6
10. HERG K+ channel expression-related chemosensitivity in cancer cells and its modu Cancer Chemother Pharmacol 56: 212-20. (2005).	105
11. Characterization of a hERG screen using the IonWorks HT: comparison to a hERG ru Assay Drug Dev Technol 3: 47-57. (2005).	102
12. Development of the predictor HERG fluorescence polarization assay using a membrane protein Assay Drug Dev Technol 6: 213-23. (2008).	102
13. [Correlation of HERG K+ channel protein expression to chemosensitivity of tumor Ai Zheng 24: 924-9. (2005).	100
14. Automated electrophysiology in the preclinical evaluation of drugs for potential J Pharmacol Toxicol Methods 52: 123-35. (0).	100
15. The Potent Inhibitory Effects of Cisapride, a Specific Blocker for Human Ether-a Cancer Biol Ther 4: 295-301. (2005).	100
16. Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ J Pharmacol Sci 95: 311-9. (2004).	100
17. Functional and pharmacological properties of canine ERG potassium channels. Am J Physiol Heart Circ Physiol 284: H256-67. (2003).	100.0
18. Development and evaluation of high throughput functional assay methods for HERG J Biomol Screen 6: 325-31. (2001).	100.0
19. Optimisation and validation of a medium-throughput electrophysiology-based hERG J Pharmacol Toxicol Methods 0: . (2006).	100
20. A QSAR model of HERG binding using a large, diverse, and internally consistent t Chem Biol Drug Des 67: 284-96. (2006).	100
21. Design, synthesis, structure-activity relationship, and in vivo activity of azab Bioorg Med Chem 0: . (2006).	100
22. Safety pharmacology assessment of drug-induced QT-prolongation in dogs with redu J Pharmacol Toxicol Methods 54: 130-40. (0).	100
23. Estimation of hERG inhibition of drug candidates using multivariate property and Bioorg Med Chem 0: . (2007).	100
24. Action potential experiments complete hERG assay and QT-interval measurements in J Pharmacol Toxicol Methods 0: . (2007).	100
25. Expression and fuactional role of HERG1, K(+) channels in leukemic cells and leu J Huazhong Univ Sci Technolog Med Sci 27: 257-60. (2007).	100
26. Expression and significance of HERG protein in gastric cancer. Cancer Biol Ther 7: . (2007).	100
27. hERG Classification Model Based on a Combination of Support Vector Machine Metho Mol Pharm 0: . (2008).	100
28. Identification of Novel Kv1.3 Blockers Using a Fluorescent Cell-Based Ion Channe J Biomol Screen 0: . (2005).	99
29. Evaluation of a high-throughput fluorescence assay method for HERG potassium cha J Biomol Screen 10: 339-47. (2005).	99
30. Identifying modulators of hERG channel activity using the PatchXpress planar pat J Biomol Screen 10: 168-81. (2005).	99
31. A novel membrane potential-sensitive fluorescent dye improves cell-based assays J Biomol Screen 7: 79-85. (2002).	99
32. HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG ri J Pharmacol Toxicol Methods 52: 136-45. (0).	97
33. Chronic inhibition of cardiac Kir2.1 and hERG potassium channels by celastrol wi J Biol Chem 0: . (2006).	95
34. Isolation and characterization of IKr in cardiac myocytes by Cs+ permeation. Am J Physiol Heart Circ Physiol 0: . (2005).	90
35. Evaluation of the rubidium efflux assay for preclinical identification of HERG b Assay Drug Dev Technol 4: 73-82. (2006).	85
36. A high-throughput HERG potassium channel function assay: an old assay with a new Drug Dev Ind Pharm 28: 177-91. (2002).	83.3
37. Application of cryopreserved cells to HERG screening using a non-radioactive Rb+ Assay Drug Dev Technol 4: 83-8. (2006).	82
38. ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non J Pharmacol Toxicol Methods 54: 116-29. (0).	79
39. Comparative evaluation of hERG potassium channel blockade by antipsychotics. Methods Find Exp Clin Pharmacol 29: 457-65. (2007).	79
40. Pharmacological separation of hEAG and hERG K+ channel function in the human mammary carci Oncol Rep 19: 1511-6. (2008).	79
41. Novel indolylindazolylmaleimides as inhibitors of protein kinase C-beta: synthes J Med Chem 48: 1725-8. (2005).	78
42. NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-s J Med Chem 47: 2089-96. (2004).	78
43. Optimization of Chromone-2-carboxamide Melanin Concentrating Hormone Receptor 1 J Med Chem 49: 6569-84. (2006).	78
44. Fluorescently Labeled Analogues of Dofetilide as High-Affinity Fluorescence Pola J Med Chem 0: . (2007).	78
45. Improved functional expression of recombinant human ether-a-go-go (hERG) K+ chan BMC Biotechnol 7: 93. (2007).	78
46. Exploring QSTR and toxicophore of hERG K(+) channel blockers using GFA and HypoG J Mol Graph Model 0: . (2007).	77
47. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofet Clin Pharmacol Ther 77: 572-82. (2005).	75
48. Early evaluation of compound QT prolongation effects: A predictive 384-well fluo J Pharmacol Toxicol Methods 0: . (2006).	75
49. Utility of hERG Assays as Surrogate Markers of Delayed Cardiac Repolarization an Toxicol Pathol 34: 81-90. (2006).	74
50. Rb+ flux through hERG channels affects the potency of channel blocking drugs: co J Biomol Screen 9: 588-97. (2004).	73
51. Preclinical cardiac safety assessment of pharmaceutical compounds using an integ Prog Biophys Mol Biol 90: 414-43. (0).	73
52. [3H]dofetilide binding to HERG transfected membranes: a potential high throughpu Eur J Pharmacol 430: 147-8. (2001).	71.4
53. The [3H]dofetilide binding assay is a predictive screening tool for hERG blockad J Pharmacol Toxicol Methods 50: 187-99. (0).	71
54. Dopamine receptor agonists differ in their actions on cardiac ion channels. Eur J Pharmacol 482: 31-7. (2003).	71
55. Drugs, hERG and sudden death. Cell Calcium 35: 543-7. (2004).	70
56. QT PRODACT: Evaluation of the Potential of Compounds to Cause QT Interval Prolon J Pharmacol Sci 99: 449-57. (2005).	70
57. Mechanism of block of the hERG K+ channel by the scorpion toxin CnErg1. Biophys J 0: . (2007).	68
58. Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc. Bioorg Med Chem Lett 0: . (2006).	67
59. Synthesis of the first sulfur-35-labeled hERG radioligand. Bioorg Med Chem Lett 16: 1692-5. (2006).	67
60. Identification of diamino chromone-2-carboxamides as MCHr1 antagonists with mini Bioorg Med Chem Lett 0: . (2006).	67
61. HERG channel trafficking. Novartis Found Symp 266: 57-69; discussi. (2005).	65
62. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molec Antimicrob Agents Chemother 49: 4721-32. (2005).	64
63. Understanding hERG inhibition with QSAR models based on a one-dimensional molecu J Comput Aided Mol Des 0: . (2007).	64
64. Use of in vitro methods to predict QT prolongation. Toxicol Appl Pharmacol 207: 446-50. (2005).	63
65. Mapping the receptor site for ergtoxin, a specific blocker of ERG channels. FEBS Lett 510: 45-9. (2002).	59
66. 1,4-Dihydroindeno[1,2-c]pyrazoles with Acetylenic Side Chains as Novel and Poten J Med Chem 0: . (2007).	58
67. Involvement of Golgin-160 in Cell Surface Transport of Renal ROMK Channel: Co-ex Cell Physiol Biochem 17: 1-12. (2006).	57
68. Combined hERG channel inhibition and disruption of trafficking in drug-induced l Br J Pharmacol 0: . (2006).	54
69. Cardiac Glycosides as Novel Inhibitors of HERG Channel Trafficking. J Pharmacol Exp Ther 0: . (2006).	54
70. Doxazosin induces apoptosis of cells expressing hERG K(+) channels. Eur J Pharmacol 0: . (2007).	51
71. Erg K+ channels modulate contractile activity in the bovine epididymal duct. Am J Physiol Regul Integr Comp Physiol 0: . (2008).	48
72. hERG channel trafficking: novel targets in drug-induced long QT syndrome. Biochem Soc Trans 35: 1060-3. (2007).	47
73. Long-QT syndrome-associated missense mutations in the pore helix of the HERG pot Circulation 104: 1071-5. (2001).	46.7
74. Acute administration of alcohol modulates pyroglutamyl amino peptidase II activi Neurochem Int 46: 347-56. (2005).	45
75. Electrophysiological effects of brompheniramine on cardiac ion channels and acti Pharmacol Res 0: . (2006).	44
76. Electrophysiological profile of propiverine – relationship to cardiac risk. Naunyn Schmiedebergs Arch Pharmacol 0: . (2007).	37
77. Bradycardia-induced long QT syndrome caused by a de novo missense mutation in th Am J Med Genet 98: 348-52. (2001).	33.3
78. QT interval prolongation: and the beat goes on. Mini Rev Med Chem 5: 1083-91. (2005).	26
79. The utility of hERG and repolarization assays in evaluating delayed cardiac repo J Cardiovasc Pharmacol 43: 369-79. (2004).	25.0
80. Analysis of the human KCNH2(HERG) gene: identification and characterization of a Hum Mutat 15: 483. (2000).	22.7